ASX Announcements
Market Sensitive
Half Yearly Report and Accounts
Half Yearly Report, Half Year Audit Review, Half Year Directors' Statement, Half Year Accounts, Half Year Directors' Report
Market Sensitive
Quarterly Activities/Appendix 4C Cash Flow Report
CTE – Second Quarter Cashflow Report, CTE - Second Quarter Activity Report
DEP Presentation at Targeted Radio Therapies Conference
Company Presentation
Change of Director's Interest Notice - Ms Cheryl Maley
Change of Director’s Interest Notice
February 2022
All the profit results for February 21, 2022
Results briefing | News and analysis on today’s profit results from Adairs, Altium, Ampol, BlueScope, Chorus, Cooper Energy, Endeavour, GDI, Hansen, Helloworld, Latitude, Lendlease, Maca, NIB, Nuix, OZ Minerals, Reliance, SelfWealth, Senex, Silver Lake, Sonic Healthcare, Starpharma, Super Retail, Tyro, Viva. Find updated reports and analysis here.
June 2021
Another speed bump for Starpharma
The bombastic biotech is facing questions from a UK regulator over claims around its COVID-19 spray nasal product. But a speed bump is nothing new.
September 2020
Starpharma launches $40m placement
Pharmaceutical and medical products developer Starpharma is seeking a cash injection to expedite the commercialisation of its coronavirus nasal spray.
August 2020
ASX up 0.2pc; NEXTDC meets guidance; Fortescue hits record
The S&P/ASX200 Index gained 9.8 points, or 0.2 per cent, t o 6126 points as iron ore miners offset weaker banks. Appen slumped as earnings, sales fall short. Woolworths gained 2.8 per cent on strong sales in July and August.
May 2020
Starpharma's coronavirus-fighting condoms
A sunscreen merchant and condom maker recently joined the scientific fight against COVID-19.
April 2020
Condom gel compound proves effective against COVID-19
Starpharma is hoping to re-purpose its antiviral compound used in its condom and vaginal gels to create a COVID-19 preventative nasal spray or eye drops.
March 2020
The CEO who swears by a sleeping pill on plane trips
Starpharma CEO Jackie Fairley believes that if there are pharmaceuticals that work well, why not use them?
January 2019
Australian biotech Starpharma approved to sell antiviral condoms in Japan
Australian biotechnology company Starpharma will start selling its antiviral VivaGel condoms in one of the world's largest condom markets after receiving final regulatory approval on Wednesday.
June 2016
Election 2016: CSIRO Manufacturing wrote Turnbull's script
CSIRO Manufacturing's partnership with Boron Molecular is the kind of industry-research collaboration the PM wants to nurture.
May 2016
Biotech Starpharma rises 6pc on Zika virus product
Melbourne-based Starpharma's stock rose 6pc after tests showed its anti-viral gel could stop sexual transmission of the epidemic.
January 2016
Biotech stocks to get the heart racing … or slowing
Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform blue chips in 2015 and are set to provide some wild rides in 2016 too.
December 2015
October 2015
Starpharma patent granted
The new patent strengthens and expands the patent protection on the VivaGel BV product.
September 2015
Starpharma product approval 'precursor to deal'
This approval is an important milestone for the company as it marks the first approval received for VivaGel for the Bacterial Vaginosis application.
Starpharma signs deal with AstraZeneca on drug delivery technology
Starpharma has inked a deal with pharmaceutical giant AstraZeneca that could be worth more than $US450 million ($650 million) a drug developed using its drug delivery technology. Its shares jumped 22 per cent on the news.
January 2015
Essential services look set for healthy returns this year
Depending on the theme investors wish to tap into there is good value among small cap healthcare and services companies. In what is shaping up as a tricky year on the sharemarket companies exposed to essential services are likely to be well supported.
Low Aussie dollar could spur biotech takeovers
A string of high-profile setbacks may have whittled away support for biotechnology companies, but executives and analysts say there is still plenty of money from overseas and the weak Australian dollar may spur a series of takeovers by foreign buyers.
October 2014
Starpharma ready to slip lubricated condom into market
Starpharma’s VivaGel condom is a world-first product and the only condom of its type that provides barrier protection and incorporates a proprietary anti-viral compound
September 2014
Starpharma looks to raise up to $15 million
Starpharma is seeking to raise between $10 million and $15 million via a placement and share purchase plan managed by Bell Potter Securities.
July 2014
Starpharma, FDA agree to trials for VivaGel
Starpharma agreement with US authorities over clinical studies of a medical gel take the group’s product one critical step closer to a regulatory submission for approval in the US.